Company Overview
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -28.77% |
| 6 Months: | -88.18% |
| 3 Months: | -86.93% |
| 1 Month: | -64.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)29.44 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 96.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VBIO Valion Bio, Inc. PHARMA | 2.50 | -0.01 | $2.22M | 0.00% | -25.51% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 126.00K | - | 0 | 86.00K | 146.00K | -302.00K | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 419.00K | 20.00K | 32.00K | 291.00K | - | - |
| Gross Profit | 22.00K | -33.00K | -26.00K | 70.00K | 125.00K | 63.00K | 113.00K | 61.00K | 108.00K | 167.00K | 30.00K | 44.00K | -239.00K | 50.00K | 54.00K | -145.00K | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.38M | 1.99M | 2.34M | 2.02M | 5.63M |
| Operating Income | -1.06M | -1.05M | -1.23M | -2.24M | -3.02M | -2.58M | -2.12M | -2.12M | -1.76M | -1.48M | -1.27M | -1.43M | - | -1.38M | -1.93M | -2.48M | -1.98M | -5.63M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.37M | -1.93M | -2.48M | -1.92M | -5.40M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 648.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.37M | -1.93M | -2.60M | -1.96M | -6.22M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.36M | -1.09M | -2.32M | -2.24M | -3.02M | -2.58M | -2.12M | -2.12M | -1.76M | -1.48M | -1.27M | -1.43M | - | -1.50M | -1.93M | -2.60M | -2.85M | -6.20M |
| Diluted EPS | -0.58 | -0.46 | -0.90 | -0.23 | -0.32 | -27.00 | -10.52 | -7.16 | -1.48 | -17.15 | -5.37 | -0.23 | - | -2.52 | -2.19 | -1.97 | - | -2.23 |
| R&D Expense | 198.00K | 192.00K | 175.00K | 401.00K | 497.00K | 399.00K | 490.00K | 468.00K | 337.00K | 256.00K | 302.00K | 422.00K | - | 335.00K | 655.00K | 858.00K | - | 1.85M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 1.84M | 1.18M | 0 | 0 |
| Cost of Revenue | 1.29M | 1.54M | 889.00K | 778.00K | - |
| Gross Profit | -38.00K | 299.00K | 287.00K | 2.00K | - |
| Operating Expenses | - | 10.40M | 8.53M | 4.48M | 7.90M |
| Operating Income | - | -10.10M | -8.24M | -4.48M | -7.90M |
| EBITDA | - | -9.92M | -8.06M | -4.12M | -7.84M |
| Interest Expense | 1.82M | - | - | 0 | 146.00K |
| Pretax Income | - | -10.10M | -8.24M | -4.47M | -7.99M |
| Tax Provision | 1.00K | - | - | - | - |
| Net Income | - | -10.10M | -8.24M | -5.66M | -8.88M |
| Diluted EPS | - | -1,768.00 | -176.80 | -19.68 | -7.84 |
| R&D Expense | 878.00K | 1.73M | 1.66M | 1.31M | 3.13M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.88M | 5.16M | 2.81M | - | - | 31.61M |
| Current Assets | - | - | 5.31M | 4.65M | 2.64M | - | - | 13.01M |
| Cash & Equivalents | - | - | 3.52M | 3.40M | 2.00M | - | - | 12.64M |
| Inventory | - | 429.00K | 863.00K | 756.00K | 319.00K | - | - | - |
| Receivables | - | 92.00K | 107.00K | 174.00K | 69.00K | - | - | - |
| Total Liabilities | - | - | 2.25M | 1.58M | 272.00K | - | - | 14.81M |
| Current Liabilities | - | - | 1.88M | 1.40M | 272.00K | - | - | 646.00K |
| Long Term Debt | - | - | - | - | - | - | - | 6.45M |
| Total Debt | - | - | 530.00K | 369.00K | 0 | - | - | 6.45M |
| Total Equity | -1.18M | - | 3.63M | 3.58M | 2.54M | 3.31M | 3.41M | 16.80M |
| Shares Outstanding | - | - | 5.69K | 86.24K | 556.98K | - | - | 2.53M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -8.92M | -8.51M | -5.72M | -7.00M |
| Investing Cash Flow | - | -11.00K | -118.00K | 0 | -705.00K |
| Financing Cash Flow | - | -528.00K | 8.51M | 4.33M | 18.35M |
| Capital Expenditure | - | -11.00K | -118.00K | - | -581.00K |
| Free Cash Flow | - | -8.93M | -8.63M | -5.72M | -7.58M |
| Net Change in Cash | - | -9.46M | -122.00K | -1.39M | 10.64M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 16.2% | 24.4% | - | - |
| Operating Margin % | - | -548.8% | -701.1% | - | - |
| Net Margin % | - | -548.7% | -701.0% | - | - |
| ROE % | - | -278.1% | -230.3% | -223.1% | -52.9% |
| ROCE % | - | -252.6% | -219.5% | -176.6% | -25.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Murchinson Ltd. | 0.52% | 4.60K | $9.75K |
| 2 | Citadel Advisors Llc | 0.33% | 2.97K | $6.29K |
| 3 | Sanctuary Advisors, LLC | 0.28% | 2.45K | $5.19K |
| 4 | Marex Group Ltd. | 0.24% | 2.17K | $4.60K |
| 5 | Virtu Financial LLC | 0.18% | 1.57K | $3.33K |
| 6 | Geode Capital Management, LLC | 0.09% | 775 | $1.64K |
| 7 | HRT Financial LP | 0.05% | 458 | $970 |
| 8 | UBS Group AG | 0.05% | 444 | $941 |
| 9 | Two Sigma Securities, LLC | 0.05% | 406 | $860 |
| 10 | Tower Research Capital LLC (TRC) | 0.01% | 84 | $178 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VBIO
Investor group in Valion Bio (VBIO) shifts to passive stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQWEVmeGN0T3U3QXNqdWV0anZuTjBoYms0Znluam1sTXRSMVN1Ukl1TTltUHVWa0lYOGstam9zU2x5Z3o0blBWSmxDQnEtdDRrYUpwTW9NcXppYXNERGZiQjVaMDZhRjNmMVBKSW1ObXFlMEhxT1VsNnBMdzNJWHJjZlJTN1JvWVg0bmxJN1…
Are High-Octane Stocks Back In Favor? Sandisk, Robinhood, Dell In Focus - Video - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMiTEFVX3lxTE5QMTlBbmZja0d0a2lrSURwaGNRY0MwOTh5NE1EaGZPVlFOQW5ZNTRWdzUyQ3RHNS1wM2Y0YlVFX3dJZTNaRUZyNF91ODk?oc=5" target="_blank">Are High-Octane Stocks Back In Favor? Sandisk, Robinhood, Dell I…
Valion Bio (VBIO) Stock Analysis Report | Financials & Insights - Benzinga
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE5IeW9Fb1l4aU9yMWd3NVladVZxZ0k0bW4yZzVTOWhTQXBlSGZQckdVdU9aYnljV0hGM2lvRXhfWmwzazZyRWF2UHBHcjRJSjNSc21YTg?oc=5" target="_blank">Valion Bio (VBIO) Stock Analysis Report | Financials …
Valion Bio Announces Reverse Stock Split - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPRUMtYVB5OFJ5Q2NUX1JELTNyRmJvR0ZBSVJtUUZjYVB3OWcwMW8tNkJfaUxOa2FLcXZhMWp3ZC1UVnoxN29yZDdIVG1mNzdOa3ZuYUtVX1BHUjJJbG9tLXlWWkloVEtzSnZKMjNBN29Fd0NWeXV5cm9iQnA0VWNnTjlkUFlQQnpnM1ZYNj…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1ZNWtmeTJfeHYwcUpkdzZxUm9TdzZ3c0dMQ0VaWl9uU3BVenpVOWNIY3d0aXNIZHFWWVM0dDFVYUFlck54Y2ZVSVlBd1NIRHly?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
3i's $16.3M note in Valion Bio (VBIO) carries a 9.99% cap - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOZ0prRlJuMmJRcHA1SEZmM0VpdDJEZHFxbkQxZ19keWdSRnNrUWl6RFZvV0JTanhsa081al9tWUJsX3dLZ2lKb0VqYnBDaThwT0stc2xRRmlXNDc5MUljTWo5V1gwTzBfWHN5QmlBdWNia1JYcWdNemhFV0dQQVllTVNkdHN1cjVLcmdYcH…
VBIO — Frequently Asked Questions
What is the current share price of Valion Bio, Inc. (VBIO)?
As of 2026-09-19 21:16 PDT, Valion Bio, Inc. (VBIO) trades at $2.50 on NasdaqCM. Its 52-week range is $2.50 to $78.75.
What is the market capitalisation of VBIO?
Valion Bio, Inc. (VBIO) has a market capitalisation of $2.22M on NasdaqCM.
What is the P/E ratio of VBIO?
VBIO trades at a trailing price-to-earnings (P/E) ratio of -0.01. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.08.
Is VBIO a good stock to buy?
This page provides a data-driven analysis of Valion Bio, Inc. (VBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.